Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-09-03 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Amalgamation/Merger
Regulatory Filings
2024-09-03 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure made under SEBI Listing Regulations regarding an order passed by the Goods and Service Tax Department related to a GST audit for the financial year 2019-2020. It includes details of the order, the company's assessment, and its intention to appeal. The document is a regulatory announcement about a legal/tax matter affecting the company, not a full financial report or audit report. It does not contain financial statements or detailed financial analysis but is a compliance disclosure as required by stock exchange regulations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-08-22 English
Updates
AGM Information Classification · 95% confidence The document is a speech delivered by the Chairman at the 31st Annual General Meeting (AGM) of Orchid Pharma Limited held on August 21, 2024. It references the Annual Report and other reports that have already been shared with shareholders but does not contain the full Annual Report itself. The content includes a summary of company performance, strategic updates, and acknowledgments typical of a Chairman's speech at an AGM. The document is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or announcement of voting results. It fits the description of AGM Information, which includes presentations and materials shared during the AGM. The document length (6244 characters) supports it being a detailed speech rather than a brief announcement. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-08-22 English
Shareholders meeting
Regulatory Filings
2024-08-21 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is titled 'Summary of Proceedings of the 31st Annual General Meeting (AGM) of Orchid Pharma Limited held on August 21, 2024.' It details the attendance, procedural aspects, resolutions considered, and voting procedures of the AGM. It does not contain the full financial statements or detailed financial performance data but rather a summary of the meeting proceedings. The document references the AGM and includes information typically disclosed in AGM proceedings such as attendance, resolutions, and voting details. Therefore, this document fits the category of AGM Information (AGM-R). The document length is over 10,000 characters, indicating it is a full summary rather than a brief announcement or notice, supporting the AGM-R classification.
2024-08-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call held on August 13, 2024, discussing the financial performance for the first quarter of fiscal year 2024-25 (Q1 FY25). It includes management's opening remarks, financial results, operational updates, and a Q&A session with analysts and investors. The text references the financial results for a quarter, contains substantive financial data and analysis, and is explicitly described as an "Earnings Conference Call" transcript. Therefore, this document fits the category of a Call Transcript (CT).
2024-08-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.